2012-12-13 18:59:13 -
Longevity of QuickStart® Camp Approach Demonstrates the Value of
Global CRO's Proven Clinical Trial Outsourcing Methodology
Raleigh, N.C., Dec. 13, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO), today announced it has reached a major
milestone with its metrics-driven clinical trial outsourcing methodology known
as the Trusted Process®, completing its 500(th) QuickStart® Camp this week.
Designed to align expectations and build study ownership across the entire
project team from the onset of a study, INC Research's QuickStart® Camp is a
unique, week-long collaborative meeting featuring a series of moderated
gatherings to drive accurate study planning and conduct proactive risk
management. The approach brings together the customer team, vendors and the
internal INC Research team to proactively work
through their drug development
programs to reduce variability and increase predictability in trial outcomes.
"Through 500 QuickStart® Camps we have continually evolved our process to
deliver the most reliable, repeatable and efficient process in the industry,"
said Jeff Kueffer, Senior Vice President, Operations Management and one of the
chief architects of the Trusted Process®. "It's extremely gratifying to have
reached this milestone. When you deliver what you say you're going to deliver,
consistently over a long period of time, customers tend to come back. To be able
to tell a customer that we can guarantee quality data and a significantly faster
start-up time, and know we can deliver on that promise without question, not
only gives them a degree of confidence that their project will be completed
faster, but also a sense of trust in the results they obtain. "
Better by Design
QuickStart® was developed from a systems engineering and fundamental project
management perspective that focused specifically on introducing efficiencies
into the study start-up process. Customers using INC Research's Trusted Process®
report faster study start-up times (four weeks faster than the industry
average), completing patient enrollment as planned and experiencing database
lock one week faster than the industry average.
Customers have fully embraced the approach. One customer recently noted,
"QuickStart® took a month's work and compressed it into a week. I'm thrilled
with the speed, but even more impressed with the high quality. INC Research
married both." Other customers have insisted they will never start a project any
The successful early implementation of QuickStart® was in turn the genesis for
the development of INC's Trusted Process® methodology. Since 2006, INC Research
has conducted all trials using its Trusted Process® methodology - a proprietary
process-oriented trial management approach that produces actionable data on time
and on budget. QuickStart® is one of four phases in INC Research's Trusted
Process clinical trials methodology. Each phase - PlanActivation®, QuickStart®,
ProgramAccelerate® and QualityFinish® - is specifically designed to maintain
high standards while driving efficiency throughout the process, which leads to a
high level of confidence to make informed decisions about study data and
For more information about the benefits of process-driven clinical research,
please view our video or download our Trusted Process® brochure.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical developmentprograms
of the highest integrity. Pharmaceutical and biotechnology companies look to INC
Research for a complete range of customized Phase I through Phase IV programs in
all therapeutic areas and innovative pediatric and women's health trials. The
company's Trusted Process(®) methodology and therapeutic foresight lead
customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at @inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE